Randomized trial · people
Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIV
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV and belly fat buildup, 26 weeks of tesamorelin cut visceral fat and improved blood fats compared with placebo, with no significant change in glucose or insulin.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 412
- Published
- 2007
- Journal
- N Engl J Med
What they tested
The team tested whether daily tesamorelin could reduce visceral fat (deep belly fat around the organs) in people with HIV who had built up abdominal fat.
How the study was done
A randomized, placebo-controlled trial at multiple centers in 412 people with HIV and extra abdominal fat, 86% of them men. They got a daily shot under the skin of either 2 mg of tesamorelin or placebo (a dummy shot) for 26 weeks, with visceral fat measured by CT scan.

What they found
Visceral fat fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group. Triglycerides (a blood fat) dropped by 50 mg per deciliter on tesamorelin and rose by 9 mg per deciliter on placebo, and the ratio of total cholesterol to HDL cholesterol fell by 0.31 versus a rise of 0.21 (P<0.001 for all). IGF-I, a growth hormone marker, rose by 81.0% on tesamorelin and fell by 5.0% on placebo, and total and HDL cholesterol also improved on tesamorelin. Glucose and insulin did not differ significantly between groups, and overall side effects were similar, though more people on tesamorelin dropped out because of a side effect.
What it doesn’t show
The trial lasted 26 weeks and enrolled mostly men with HIV and abdominal fat buildup, so it does not show longer-term effects or results in other groups. It measured fat and blood markers, not heart attacks or other heart outcomes.
The paper
Falutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.